Screen for acute leukaemia, blast crisis, suspected leucostasis and sepsis. Urgency depends on the clinical state, differential count, blood-film findings, haemoglobin and platelet results, rate of change, organomegaly and symptoms—not the total WCC alone. Follow the laboratory comment and local haematology referral pathway.
Hyperleukocytosis (WCC ≥100 × 10⁹/L) can cause leucostasis, but the risk varies with the underlying disease, blast count, myeloid versus lymphoid lineage, symptoms, platelet and haemoglobin results and biochemical evidence of tumour lysis. A numerical WCC threshold does not automatically mandate a 999 ambulance in a clinically stable patient; diagnosing and managing leucostasis/hyperviscosity is haematology-led.
Blast cells indicate acute leukaemia (AML/ALL). Some laboratory “blast” or “immature cell” flags need confirmation by a manual film, so contact the reporting haematologist/pathologist or local haematology advice line rather than automatically sending every patient by 999.
B symptoms (fever, sweats, weight loss) in the context of leucocytosis suggest haematological malignancy. NICE NG12 sets very urgent FBC and suspected cancer pathway referral routes for suspected haematological cancer.
Septic leucocytosis can be marked (leukaemoid reaction). The leucocytosis is secondary; the priority is identifying and treating the source of infection urgently.
Confirm persistent leucocytosis and identify the predominant white cell lineage. A single raised WCC may be transient (infection, stress, exercise); a single isolated mild leucocytosis with a clear explanation in a well patient is often reactive and does not need immediate repeat testing.
Transient leucocytosis is common after infection, stress, exercise, or smoking. A single raised WCC does not mandate extensive investigation. Repeating the FBC avoids unnecessary anxiety and costly tests.
The differential is key. Neutrophilia (infection, inflammation, medicines, smoking; rarely CML — neutrophilia itself does not indicate bacterial infection), lymphocytosis (viral infection, CLL), eosinophilia (allergy, parasites), and monocytosis (chronic infection, CMML) each have distinct causes and management pathways.
Blood film review by a haematologist can detect morphological abnormalities (blasts, smudge cells, left shift) that automated counters miss. It is the single most important diagnostic step after confirming persistent elevation.
Classify leucocytosis by the cell type that is elevated. This determines the differential diagnosis and investigation pathway.
Neutrophilia is the most common leucocytosis pattern. Most are reactive (infection, inflammation, steroids, smoking). Persistent unexplained neutrophilia, especially with left shift, basophilia or splenomegaly, raises concern for CML.
Lymphocytosis: CLL requires a persistent clonal B-cell lymphocytosis (generally ≥5 × 10⁹/L for at least 3 months) confirmed by immunophenotyping (CD5+/CD19+/CD23+). Request flow cytometry through the local haematology pathway or according to laboratory criteria, rather than automatically for every lymphocyte count >5 × 10⁹/L.
Eosinophilia requires a full history including travel and medication. Patients who are otherwise well with mild eosinophilia (0.5–1.5 × 10⁹/L) may not require extensive testing; persistent eosinophilia ≥1.5 × 10⁹/L or eosinophilia with systemic symptoms/organ involvement warrants further assessment (BSH 2017). Before prescribing systemic corticosteroids to a patient with unexplained eosinophilia and relevant travel/exposure history, consider Strongyloides testing or specialist advice — untreated strongyloidiasis can become life-threatening after immunosuppression.
Basophilia is rare and is not pathognomonic for CML. In CML, basophils are often accompanied by the entire spectrum of myeloid maturation on blood film (left shift).
Examine for splenomegaly, hepatomegaly, and lymphadenopathy. These findings narrow the differential and guide referral urgency.
Splenomegaly in leucocytosis is highly significant. Massive splenomegaly suggests CML, myelofibrosis, or hairy cell leukaemia. Moderate splenomegaly occurs in CLL, lymphoma, and infectious mononucleosis.
Lymphadenopathy differentiates malignant from reactive causes. Unexplained lymphadenopathy or splenomegaly, especially with fever, night sweats, weight loss, pruritus or breathlessness, should prompt consideration of a suspected cancer pathway referral (NICE NG12); there is no universal node-size or duration rule. Tender, mobile nodes suggest reactive hyperplasia.
Hepatomegaly + splenomegaly together strongly suggest haematological malignancy (CML, CLL, lymphoma) or chronic infection (EBV, CMV). Isolated hepatomegaly is more often due to liver pathology or heart failure.
Investigate based on the predominant cell lineage and clinical context. Avoid shotgun testing; target investigations to the likely differential.
Blood film review is the single highest-yield investigation. It can identify acute leukaemia, CML, CLL and infectious mononucleosis, and morphological abnormalities that automated differentials may miss.
Flow cytometry (immunophenotyping) is diagnostic for CLL (CD5+/CD19+/CD23+). It can be performed on peripheral blood and does not require bone marrow biopsy in most cases. Request it through the local haematology pathway.
LDH elevation is non-specific but indicates high cell turnover. Seen in haematological malignancy, haemolysis, tissue injury and tumour lysis syndrome. Interpret alongside the film and clinical picture; no single LDH value is a referral threshold.
Targeted investigation based on predominant cell type avoids unnecessary tests and anxiety. A patient with isolated neutrophilia does not need parasite serology; a patient with eosinophilia does not need BCR-ABL testing.
Refer based on the clinical state, differential count, blood film findings, cytopenias, rate of change, organomegaly and symptoms — not the total WCC alone. Use the local laboratory abnormal-result pathway and haematology referral guideline.
Total WCC alone does not set urgency. Hyperleukocytosis with symptoms, a rapidly rising count, blasts or cytopenias warrants same-day haematology discussion; a stable patient with a high count needs urgent haematology involvement, with setting and transport determined by the clinical state.
Persistent lymphocytosis needs the absolute count, film and clinical context; CLL requires clonality confirmed by immunophenotyping, arranged through the local haematology pathway (BSH CLL guideline 2025). NICE NG12 covers symptom-based suspected haematological cancer referral.
Reactive leucocytosis (infection, steroids, smoking, stress) is common in primary care. It does not require haematology referral if the WCC settles once the underlying cause has been treated.
Blood film abnormalities (blasts, left shift, smudge cells) mandate referral even if WCC is only mildly elevated. Morphology is more important than absolute count in detecting malignancy.
Leucocytosis is a symptom, not a disease. Treatment targets the underlying cause. Primary care can manage reactive causes; haematological malignancy requires specialist input.
Haematological malignancy treatment: Managed by haematology. Primary care role is supportive care, monitoring for complications, and managing treatment side effects.
Next steps: see Haematological cancers · Smoking cessation
Reactive leucocytosis resolves when the underlying cause is treated. Treating infection, reviewing medicines, smoking cessation and discontinuing causative drugs address the cause. There is no role for treating the WCC itself.
CLL watch-and-wait is evidence-based. Early chemotherapy does not improve survival in asymptomatic CLL. Treatment is reserved for symptomatic disease (bulky nodes, cytopenia, B symptoms) and is haematology-led.
Parasite treatment for eosinophilia should be guided by the confirmed or suspected parasite and local or specialist advice. Stool microscopy has low sensitivity for strongyloides; seek infectious-diseases advice before presumptive treatment in high-risk patients (especially before steroids or immunosuppression).
Lifestyle interventions reduce cardiovascular and infection risk in patients with chronic leucocytosis, particularly those with haematological malignancy.
Smoking cessation is offered for general health benefit; it may help a smoking-related mild neutrophilia, but a WCC response is not guaranteed.
Infection prevention is critical in CLL and other lymphoproliferative disorders. Hypogammaglobulinaemia is common in CLL and increases infection risk; offer flu and pneumococcal vaccination.
Thrombosis risk is increased in myeloproliferative disorders (ET, PV). Aspirin and cytoreductive therapy are haematology-led decisions; aspirin may be contraindicated depending on platelet count, bleeding risk and specialist management.
Exercise improves quality of life and reduces fatigue in haematological malignancy. Avoid contact sports if the platelet count is low or the spleen is enlarged, and follow haematology advice on safe activity.
Follow-up depends on the likely cause and the initial results. Repeat testing after the suspected reactive cause has resolved, using the laboratory comment and local referral guidance. Escalate sooner if the WCC rises, the differential becomes abnormal, cytopenias develop, blasts appear, organomegaly is found or systemic symptoms emerge.
WCC trajectory is more important than absolute value. A rising WCC (e.g., 12 → 15 → 20 over 3 months) suggests malignancy or evolving myeloproliferative disorder even if each individual value is not alarm-level.
CLL progression is monitored according to the specialist plan. Contact haematology earlier for a rapidly rising lymphocyte count, new cytopenia, progressive lymphadenopathy or splenomegaly, or B symptoms.
Symptoms suggesting leucostasis (headache, visual changes, confusion, breathlessness) are medical emergencies requiring emergency assessment; diagnosis and management are haematology-led.
Patient anxiety about leucocytosis is common. Clear explanation, regular monitoring, and low threshold for haematology referral reduces distress. Many patients fear cancer; early specialist reassurance (even if benign) improves quality of life.